Home › Research › Emerging Healthcare
Sector Thesis · Emerging HealthcareAI healthcare & telehealth stocks: the re-rating thesis
Why this sector, and why now
Much of digital health de-rated hard after the pandemic bubble, leaving real businesses trading like failures. The thesis is selective re-rating: the ones with growing revenue and a genuine AI or DTC edge can recover from depressed levels.
AI drug discovery is the higher-risk, higher-reward end — using machine learning to compress the discovery timeline — while DTC telehealth is the steadier compounding story underneath.
The names that express the thesis
| TICKER | LAST | DAY | ROLE |
|---|---|---|---|
| HIMS Hims & Hers | $31.47 | +5.0% | Direct-to-consumer telehealth; the DTC growth story |
| DOCS Doximity | $20.89 | +1.2% | Healthcare network + AI tools for clinicians |
| RXRX Recursion | $3.18 | −2.8% | AI-driven drug discovery (higher risk/reward) |
| TDOC Teladoc | $7.57 | +2.7% | Telehealth incumbent; the re-rating candidate |
Last close, June 16, 2026 session — illustrative, not recommendations. Prices move; the thesis is the structure.
Track every sector like a professional.
Grab the free ZNR Trade Journal — a pre-built Excel system that breaks your performance down across all 10 sectors. Plus the free 3x/week briefing.
Get the free Trade Journal Read the briefingBy the numbers
The structural signals behind the trade — the data that actually moves these names:
- Hims & Hers (HIMS) is the DTC growth engine of the group — a consumer-health brand with a recurring revenue model.
- Recursion (RXRX) represents the AI-drug-discovery end: high optionality, binary outcomes, and a multi-year horizon.
- Several names (e.g., Teladoc, TDOC) trade far below their pandemic peaks — the bet is on selective recovery, not a sector-wide bounce.
What to watch
- Revenue growth and path to profitability at the DTC names
- AI drug-discovery pipeline read-outs
- Reimbursement and telehealth-policy changes
- Cash burn at the early-stage names
The honest risk
This is a stock-picker's sector — plenty of value traps sit next to the real businesses. AI drug discovery is especially binary, and policy/reimbursement shifts can reset the whole group. Differentiate ruthlessly between growing franchises and falling knives.
Zero Noise Report tracks all 10 sectors three times a week using live market data and primary-source company disclosures — not press-release hype. This page is the evergreen version of a thesis we revisit as the data moves; the "Updated" date reflects the last review. We hold no positions in the names mentioned and run no ads. Tickers illustrate the structure of the trade, never as recommendations.
FAQ
What is the emerging healthcare thesis?
Two catalysts in a beaten-down sector: AI-accelerated drug discovery (e.g., Recursion, RXRX) and the durable shift to direct-to-consumer digital health (e.g., Hims & Hers, HIMS).
Why is the sector beaten down?
Much of digital health bubbled during the pandemic and then de-rated hard — which is exactly why selective recovery is the thesis.
Which is safer, telehealth or AI drug discovery?
Telehealth/DTC names tend to have real revenue and clearer paths; AI drug-discovery names are more binary and speculative.